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Summary. In thrombus formation associated with 
hemostasis or thrombotic disease, blood platelets first 
undergo a rapid transition from a circulating state to an 
adherent state, followed by activation and aggregation. 
Under flow conditions in the bloodstream, this process 
potentially involves platelet-platelet,  platelet- 
endothelium, platelet-subendothelial matrix, and 
platelet-leukocyte interactions. Specific adhesion 
receptors on platelets mediate these interactions, by 
engaging counter-receptors on other cells, or non- 
cellular ligands in the  plasma or  matrix. The  
glycoprotein (GP) Ib-IX-V complex on platelets initiates 
adhesion at high shear stress by binding the adhesive 
ligand, von Willebrand Factor (vWF). GP Ib-IX-V may 
also mediate platelet-endothelium or platelet-leukocyte 
adhesion, by recognition of P-selectin or Mac-1, 
respectively. Other membrane glycoproteins, such as the 
collagen receptor GP VI, may trigger platelet activation 
at low shear rates. Engagement of GP Ib-IX-V or GP VI 
leads ultimately to platelet aggregation mediated by the 
integrin, aIIbB3 (GP IIb-IIIa). This review will focus on 
recent advances in understanding structure-activity 
relationships of GP Ib-IX-V, its role in initiating 
thrombus formation, and its emerging relationships with 
other vascular cell adhesion receptors. 
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lntroduction 
The classical view of thrombus formation in the 
hemostatic response to vessel wall injury i s  that 
circulating platelets recognize exposed subendothelial 
matrix, adhere to the site, become activated, and recruit 
additional platelets to produce an aggregate or thrombus. 
Similarly, in thrombotic disease, platelet aggregation 
may be induced by sclerotic plaque rupture to expose the 
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underlying matrix, or by pathological turbulent shear 
stress in blocked vessels (Kroll et al., 1996; Andrews et 
al., 1997; Savage et al., 1998). At high shear stress in the 
vasculature, both platelet adhesion and shear-induced 
platelet aggregation are initiated by the platelet 
membrane glycoprotein (GP) Ib-IX-V complex binding 
to the adhesive glycoprotein, von Willebrand Factor 
(vWF) present in plasma or the subendothelial matrix. 
More recently, it has been recognized that platelets may 
roll on the surface of the matrix or endothelium prior to 
arrest (Frenette et al., 1995, 1998; Savage et al., 1996; 
Denis et al., 1998; Cranmer et al., 1999; Andre et al., 
2000; Kulkarni et al., 2000). Interestingly, the process of 
platelet rolling on the vessel wall followed by tight 
adhesion resembles the inflammatory response, where 
circulating leukocytes first roll, then become tightly 
adherent on activated endothelium, prior to extravasation 
(Berndt et al., 2001; Siegelman, 2001). Adhered, 
activated platelets attached to vessel wall matrix also 
support rolling of leukocytes under flow (Katayama et 
al., 2000; Simon et al., 2000). Many of the adhesion 
receptors that mediate leukocyte adhesion are also 
involved in platelet-matrix, platelet-endothelium or 
platelet-leukocyte adhesion. 
The network of interactions between vascular cell 
adhesion receptors is shown in Fig. 1. Receptors that are 
reportedly expressed on platelets are highlighted. As 
evident from this diagram, interactions commonly occur 
between receptors from particular protein families. For 
instance, integrins may recognize one or more members 
of the immunoglobulin (Ig) superfamily, and vice-versa 
(Fig. 1). In a similar vein, selectins favor an association 
with sulfated, sialomucin-like receptors. Notably, many 
of the receptors in Fig. 1 have the capacity to bind to 
more than one counter-receptor. This confers the ability 
of these receptors to mediate adhesion between different 
types of vascular cells. For example, GP Ib-IX-V of the 
leucine-rich repeat protein family enables platelets to 
interact with endothelial cells via P-selectin (Romo et 
al., 1999), and with neutrophils or monocytes via the 
aM02 integrin, Mac-1 (Simon et al., 2000), as well as to 
interact with subendothelial matrix by binding vWF. 
This review will primarily focus on GP Ib-IX-V, 
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which plays a central role in platelet adhesive 
interactions at high shear stress (Fig. l), and additionally 
regulates platelet activation by an interaction with a- 
thrombin. 
Leucine-rich repeat receptor: the GP lb-IX-V complex 
GP Ib-IX-V is  a complex of four membrane- 
spanning polypeptides, GP Iba, GP IbB, GP IX and GP 
V (Fig. 2) (López, 1994). Al1 of these subunits are 
members of the leucine-rich protein family, and contain 
one (GP IbB and GP IX), seven (GP Iba) or fifteen (GP 
V) conserved -24-residue leucine-rich repeats in their 
extracellular domains. The repeats in each subunit of GP 
Ib-IX-V are flanked at their N- and C-termini by 
conserved disulfide-looped sequences. These repeats, 
and often their flanking sequences, are distributed in a 
wide range of proteins from diverse species (López, 
1994). GP Iba contains a highly O-glycosylated mucin- 
like domain that separates its globular N-terminal region 
from the platelet membrane. This N-terminal region of 
282 amino acid residues consists of an N-terminal flank 
sequence (Hisl-Ile35), seven leucine rich repeats 
(Leu36-Ala200), a C-terminal flank sequence (Phe201- 
Gly268), and an anionic sequence (Asp269-Glu282) 
which contains three sulfated tyrosine residues (Tyr276, 
Tyr278 and Tyr279). This 282-residue sequence of GP 
Iba is the major ligand-binding region of the GP Ib-IX- 
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V complex, with binding sites for vWF, P-selectin, Mac- 
1,  thrombin, factor XII and high molecular weight 
kininogen (refer below). Another notable feature of the 
GP Ib-IX-V structure is a thrombin cleavage site on GP 
V (Fig. 2), which results in a soluble extracellular 
fragment of GP V being released following thrombin 
treatment of platelets (Berndt and Phillips, 1981). 
The cytoplasmic domain of the GP Ib-IX-V complex 
is made up of the cytoplasmic tails of GP Iba  (-100 
residues), GP IbB (-34 residues), GP V (-16 residues) 
and GP IX (-5 residues). The cytoplasmic sequence of 
GP Iba  contains a binding site for the cytoskeletal 
protein, actin-binding protein, within Thr536-Phe568 
(Andrews and Fox, 1992; Cunningham et al., 1996). 
Signaling proteins such as 14-3-3G (Du et al., 1994) and 
the p85 subunit of phosphatidyl inositol (PI) 3-kinase 
(Munday et al., 2000) also interact with the cytoplasmic 
domain of the complex. 14-3-35 binds to the C-terminal 
sequence of GP Iba [Ser606-Gly-His-Ser(P)-Leu] (Du et 
al., 1996; Andrews et al., 1998). Ser-609 has recently 
been shown to be stably phosphorylated in resting 
platelets, but the responsible kinase has not been 
identified (Bodnar et al., 1999). There is also a 14-3-3- 
binding sequence, Arg-Leu-Ser-Leu-(Ser/Thr)-Asp-Pro, 
within the cytoplasmic domain of GP IbB, encompassing 
the protein kinase A (PKA) phosphorylation site at 
Ser166 (Du et al., 1996; Andrews et al., 1998; Calverley 
et al., 1998). Phosphorylation of Ser166 in GP IbB 
Fig. 1. Networking of adhesion receptors (circled) on vascular cells. Horizontal rows correspond to protein families as indicated in the column on the 
left. Shaded circles represent receptors that are reportedly expressed on platelets. 
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enhances 14-3-35 association (Calverley et al., 1998; 
Feng et al., 2000), and also inhibits actin polymerization 
in response to platelet activation (Fox and Berndt, 1989). 
The potential functional significance of these 
interactions between the cytoplasmic domain of GP Ib- 
IX-V and actin-binding protein, 14-3-3< and PI 3-kinase 
is discussed below. 
lnteraction of GP lb-IX-V and vWF 
In contrast to normal blood, thrombus formation is 
dramatically impaired in blood from patients with 
Bernard-Soulier syndrome (deficient or dysfunctional 
platelet GP Ib-IX-V) or type 3 von Willebrand's disease 
(lack of plasma and platelet vWF) (Sadler et al., 1995; 
Mpez et al., 1998; Tsuji et al., 1999). In the absence of 
functional GP Ib-IX-V or vWF, platelet-vessel wall 
interaction is defective at high shear (>1,210 S-l), but 
normal at low shear (e340 S-l) (Tsuji et al., 1999). 
Studies with Bernard-Soulier syndrome or type 3 von 
Willebrand's disease platelets suggest the interaction 
between GP Ib-IX-V and vWF is critica1 for thrombus 
formation at high shear, whereas other receptors mediate 
platelet adhesion and aggregation at low shear. 
vWF is a multimeric, disulfide-linked glycoprotein 
composed of subunits of 2,050 residues (Ruggeri, 1999). 
vWF has a modular structure, .consisting of domains D'- 
D3-Al-A2-A3-D4-Bl-B2-B3-Cl-C2. The A l  domain, 
encompassing the intramolecular Cys509-Cys695 
disulfide bond, contains the binding site for GP I b a  
(Andrews et al., 1997). This recognition site is not in an 
active state in the native molecule, preventing binding of 
plasma vWF to platelets in the normal circulation, but 
undergoes conformational activation when associated 
with subendothelial matrix. The vWF A l  domain may 
also be activated in vitro by non-physiological 
modulators, such a s  the bacteria1 glycopeptide, 
ristocetin, from Nocardia lurida (Bemdt et al., 1992), or 
the viper venom proteins, termed botrocetins, from 
Bothrops jararaca (De Luca et al., 1995b; Fujimura et 
al., 1996;  Andrews and Berndt, 2000b). These 
structurally different reagents induce conformational 
activation of the A l  domain by binding to distinct sites. 
Ristocetin mainly recognizes a negatively charged, 
proline-rich sequence, Glu700-Asp709, flanking the 
Cys509-Cys695 disulfide bond (Bemdt et al., 1992; De 
Luca et al., 2000), whereas botrocetins bind to more 
positively-charged site(s) within the disulfide loop 
(Andrews et al., 1997; Andrews and Berndt, 2000b). The 
anti-vWF monoclonal antibody 6G1 also activates the 
vWF A l  domain, like ristocetin, by an interaction with 
the proline-rich sequence, Glu700-Asp709 (De Luca et 
al., 2000). Another anti-vWF A l  domain antibody, 
MoAb724, also induces GP Ib-dependent platelet 
aggregation, but appears to mimic botrocetin 
(Depraetere et al., 1998). In contrast, a viper venom 
protein, bitiscetin, from Bitis arietans activated the A l  
domain of vWF to bind GP Ib-IX-V by binding to the 
vWF A3 domain, a region that also interacts with 
collagen type 111 (Obert et al., 1999). 
vWF may also be activated by a number of 
congenital gain-of-function mutations within the vWF 
gene (Type 2b von Willebrand's disease). These result in 
mainly single amino acid substitutions within the A l  
domain (Andrews et al., 1997). Many of these are 
clustered at the C-terminal end of a postulated GP Iba- 
binding sequence, Asp514-Glu542 (Berndt et al., 1992). 
A discontinuous sequence(s) of vWF may also be 
involved in GP Ib-IX-V binding, since mutation of 
Lys599Ala in a recombinant vWF fragment inhibited the 
Flg. 2. Schematic of the GP lb-IX-V 
complex, consistlng of GP Iba, GP 
IbB, GP IX and GP V in the ratio 
2:2:2:1. The N-terminal, ligand- 
binding domain of GP Iba (Hisl- 
Glu282) consists of seven leucine- 
rich repeats, the disulfide-linked N- 
terminal and C-terminal flank 
sequences, and the sulfated tyrosine 
containing sequence (Asp269- 
Glu282). Critical regions of GP Iba 
for binding W F  (leucinarich repeats 
2-4) and a-thrombin (sulfated region) 
are indicated. Potential N-linked 
glycosylation sites (Asn-X-SerlThr) 
are also indicated (shaded circles). 
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ristocetin-dependent interaction (Matsushita et al., 
2000). Hi h physiological (>650 S-l) or pathological F (>1,200 S- ) shear rates may also activate vWF, although 
shear-dependent vWF binding to GP Ib-IX-V may also 
involve activation at the leve1 of the receptor (López et 
al., 1998). 
Elements implicated in recognition of vWF by GP 
Ib-IX-V occur within al1 four structural regions of the N- 
terminal 282 residues of GP Iba: the N-terminal flank 
(Hisl-Ile35), the seven leucine-rich repeats (Leu36- 
Ala200), the C-terminal flank (Phe201-Gly268), and the 
sulfated tyrosine sequence (Asp269-Glu282). This 
presumably reflects conformational requirements of the 
receptor for  optimal v W F  binding. Supporting a 
functional role for the leucine-rich repeats is a form of 
Bernard-Soulier syndrome where GP Iba is expressed in 
a dysfunctional form that does not bind vWF (López et 
al., 1998). This form of GP Iba contains a single amino 
acid substitution (Leu57lPhe) within the first leucine- 
rich repeat (Miller et al., 1992). Similarly, GP I b a  
associated with the Bolzano variant of Bernard-Soulier 
syndrome contains an Ala156lVal mutation within the 
sixth leucine-rich repeat, and this mutation causes 
dysfunctional vWF binding, but normal thrombin 
binding (Ware et al., 1993). Further, we have recently 
produced a series of canine-human and human-canine 
chimeras of recombinant GP Iba,  corresponding to 
structural domain boundaries. Binding of chimera- 
expressing cells to soluble vWF in the presence of 
ristocetin, or to immobilized vWF under flow in the 
absence of modulators, suggested that leucine-rich 
repeats 2-4 of GP Iba  were a critica1 requirement for 
vWF binding (Shen et al., 2000). These chimera- 
expressing cell lines were also used to map epitopes for 
a panel of anti-GP Iba monoclonal antibodies that bound 
to human, but not canine, GP Iba  (Shen et al., 2000). 
Antibodies that strongly inhibited ristocetin-induced 
binding (AK2, Hipl, 6D1) mapped to sites within the 
first four leucine-rich repeats. Another inhibitory 
antibody, AP1, mapped to the C-terminal flank, whilst 
partially blocking antibodies, MB45 and AN51, mapped 
to the N-terminal flank. Other antibodies that preferably 
blocked botrocetin-induced vWF binding, VM16d or 
SZ2, recognized the C-terminal flank or sulfated tyrosine 
sequence, respectively (Ward et al., 1996; Shen et al., 
2000). Earlier studies identified synthetic peptides based 
on leucine-rich repeat sequences, Thr81-Leu95 or 
Leu136-Leu150, as well as downstream sequences, 
Asp235-Lys262, Ser251-Tyr279, Gly271-Glu285, as 
potentially mediating ristocetin- or botrocetin-dependent 
vWF binding (Katagiri et al., 1990; Vicente et al., 1990). 
There is emerging evidence suggesting the disulfide- 
looped C-terminal domain flanking the leucine-rich 
repeats is involved in regulating vWF binding. The C- 
terminal flank domain (Phe201-Gly268) is composed of 
two disulfide loops by virtue of disulfide bonds between 
Cys209-Cys248 and Cys211-Cys264 (López, 1994). 
Congenital gain-of-function mutations within the GP 
Iba gene ("platelet-type" or "pseudo" von Willebrand's 
disease) result in single amino acid substitutions, 
Gly233Nal or Met239Na1, within the first of the two 
disulfide-loops (Miller et al., 1991; Russell and Roth, 
1993; Miller, 1996). Mutation of Gly233 or Met239 to 
valine in recombinant GP  Iba ,  in addition to the 
artificial mutations Asp2351Val or Lys237/Val, also 
result in a gain-of-function phenotype (Marchese et al., 
1999; Dong et al., 2000). In contrast, an Ala238lVal 
mutation resulted in partial loss of function (Dong et al., 
2000). 
Finally, the sulfated tyrosine sequence of GP Iba, 
Asp269-Glu282, also contributes to vWF binding under 
certain conditions. Studies with recombinant GP Iba 
expressed in mammalian cells provided evidence that 
blocking sulfation of Tyr276, Tyr278 and Tyr279 
diminished ristocetin-dependent vWF binding, and more 
strongly inhibited botrocetin-dependent binding (Dong 
et al., 1994; Marchese et al., 1995). An unsulfated, 
cathepsin G-generated fragment of native GP Iba (Hisl- 
Leu275) was an order of magnitude less effective than a 
sulfated mocarhagin-derived fragment (Hisl-Glu282), a 
trypsin fragment (Hisl-Arg293) or the full length soluble 
receptor at inhibiting botrocetin-dependent vWF binding 
(Ward et al., 1996). Further, mutagenesis of recombinant 
GP I b a  showed that anionic residues between 
Asp252-Asp277 were involved in botrocetin-dependent 
vWF binding, and contributed to a lesser extent to 
ristocetin-dependent binding, while residues between 
Glu281-Asp287 showed a much greater affect on 
botrocetin-dependent binding (Murata et al., 1991). 
While these sites are potentially important in regulating 
platelet adhesion to vWF, analysis of the modulator- 
independent interaction of GP Iba with vWF under flow 
suggests this interaction more closely parallels 
ristocetin-dependent vWF binding (Dong et al., 2001). 
Both interactions predominantly involve the more N- 
terminal sites described above Some antibodies, 
however, against either GP Iba or vWF only inhibit the 
shear-dependent interaction (Cauwenberghs et al., 2000; 
Dong et al., 2001). 
Mac-1 binding to GP lb-IX-V 
The leukocyte integrin, Mac-1 (aMB2) is a recently 
described ligand for GP Ib-IX-V (Simon et al., 2000). 
Inhibition studies with monoclonal antibodies and 
receptor fragments showed that the interaction involved 
the 1 domain of Mac-1 (homologous to the vWF A l  
domain), and the N-terminal region of GP I b a  
containing the leucine-rich repeats and flanking 
sequences (Hisl-Glu282). One of the inhibitory anti-GP 
Iba  antibodies, VM16d, mapped into the C-terminal 
flank of GP Iba, and this antibody also blocks vWF 
binding induced by botrocetin and thrombin-dependent 
platelet aggregation (Mazurov et al., 1991; Shen et al., 
2000). Wild type, but not Mac-1 deficient mouse 
neutrophils, bound to purified GP I b a  or adherent 
platelets. These findings imply that GP Ib-IX-V may 
mediate binding of platelets to leukocytes via Mac-l. 
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This interaction could thereby promote inflammation at 
thrombotic or atherosclerotic sites (Simon et al., 2000). 
In particular, this binding interaction may be most 
relevant to transmigration of macrophages through mural 
thrombus (Simon et al., 2000), a process required for 
vessel remodeling post-angioplasty. 
P-selectin, a further GP lb-IX-V ligand 
P-selectin is an adhesion receptor of the selectin 
family, and is associated with the a-granules of platelets 
and the Weibel-Palade bodies of endothelial cells. It is 
expressed on the cell surface following activation 
(Kansas, 1996). vWF is also found in both of these 
storage organelles. P-selectin is a transmembrane 
glycoprotein, consisting of an N-terminal ca2+-  
dependent lectin-like domain, an epidermal growth 
factor-like domain, and nine complement regulatory 
protein repeats in the extracellular region. On activated 
endothelial cells, P-selectin mediates initial contact and 
rolling of circulating neutrophils by a specific interaction 
with P-selectin glycoprotein ligand-1 (PSGL-1). 
Elements from within both the lectin-like and epidermal 
growth factor-like domains are involved in PSGL-1 
recognition (Kansas et al., 1994; Mehta et al., 1997). A 
recent report also places PSGL-1 on platelets (Frenette et 
al., 2000). Although its precise role on platelets has not 
been fully defined (Frenette et al., 2000), it could be 
involved, along with GP Ib-IX-V, in supporting platelet 
rolling on activated endothelium. 
PSGL-1 and GP I b a  show a notable degree of 
structural similarity (Andrews et al., 1997, 1999; Berndt 
et al., 2001). Both GP Iba and PSGL-1 are sialomucins 
that contain sulfated tyrosine sequences within their N- 
terminal domains. Like PSGL-1, GP I b a  also 
specifically binds P-selectin (Romo et al., 1999). P- 
selectin-expressing cells adhered to immobilized GP 
Iba, whilst GP Iba-expressing cells adhered and rolled 
on either purified P-selectin or activated endothelial 
cells. Unlike P-selectin binding to PSGL-1, binding to 
GP Iba was independent of both ca2+, and receptor 
fucosylation. However, binding to both PSGL-1 and GP 
Iba appeared to involve, at least in part, their sulfated 
tyrosine motifs (De Luca et al., 1995a; Pouyani and 
Seed, 1995; Romo et al., 1999). The physiological 
consequences of GP I b a  binding to P-selectin are 
unclear, however the interaction potentially contributes 
to platelet adhesion to activated endothelium. Supporting 
a role in thrombus formation, recent studies using 
intravital microscopy in mice where the P-selectin-GP 
Ib-IX-V interaction was blocked showed attenuated 
rolling of platelets, as well as leukocytes, on the vessel 
wall (Katayama et al., 2000). 
lnteraction of GP lb-IX-V with a-thrombin, factor XII 
and kininogen 
The evidence that GP Ib-IX-V interacts with a- 
thrombin, and facilitates thrombin-dependent platelet 
activation, has recently been reviewed (Berndt et al., 
2001). The N-terminal region of GP Iba contains a high 
affinity binding site for thrombin (Mpez, 1994; Greco et 
al., 1996), and deficiency or blockade of GP Ib-IX-V 
impairs thrombin-dependent platelet aggregation 
(Yamamoto et al., 1985; Ward et al., 1996; Mpez et al., 
1998; De Candia et al., 1999). The sulfated tyrosine 
sequence of GP Iba  (Asp269-Glu282) constitutes a 
major thrombin recognition sequence (De Marco et al., 
1994; Gralnick et al., 1994; Marchese et al., 1995; Ward 
et al., 1996; Mazzucato et al., 1998; De Cristofaro et al., 
2000). A second site within the leucine-rich repeats 
(Phe216-Thr240) may also participate in thrombin 
binding (Katagiri et al., 1990; McKeown et al., 1996). 
The demonstration of a direct relationship between 
thrombin binding to the sulfated region of GP Iba and 
cleavage of the seven-transmembrane thrombin receptor, 
PAR-1, suggested GP Iba may function as a cofactor for 
thrombin-dependent PAR-1 activation (De Candia et al., 
2001). Thrombin also cleaves GP V near the membrane 
(Arg476) to release an extracellular soluble fragment 
(Berndt and Phillips, 1981). Recent studies using 
platelets from GP V-null mice suggest the GP Ib-IX-V 
complex is itself a thrombin receptor (Ramakrishnan et 
al., 2001). It was shown that proteolytically-inactive 
thrombin activates GP V null platelets, as well as wild- 
type mouse and human platelets, after cleavage of GP V 
by thrombin. Catalytically inactive thrombin also 
induced thrombosis in GP V null mice but not wild-type 
mice. Thrombin binding to GP Iba following cleavage 
of GP V initiated signaling responses and ADP secretion 
(Ramakrishnan et al., 2001). These findings imply a role 
for GP V as a negative regulator of thrombin-dependent 
platelet activation. Interestingly, expression of GP V, 
along with GP Iba, is required for optimal binding of 
thrombin to L cells transfected with GP Iba andlor GP V 
(Dong et al., 1997). 
Thrombin binding to GP Ib-IX-V also accelerates 
coagulation at the activated platelet surface (Dormann et 
al., 2000). Thrombin binding to GP I b a  enhances 
phospholipid exposure on the platelet surface, and this 
interaction contributes to increased thrombin generation. 
In contrast, it has been reported that GP Iba binding to 
thrombin causes conformational changes in thrombin 
that allosterically reduce cleavage of fibrinogen (or 
peptide substrates) (Li et al., 2000). The physiological 
consequences of thrombin binding to GP Ib-IX-V, 
therefore, is likely to depend on thrombin concentration, 
the extent of GP V cleavage, and the prevalence of 
inhibitors of the thrombin-GP I b a  interaction. For 
example, two newly described GP Ib-IX-V ligands, 
factor XII and high molecular weight kininogen, regulate 
thrombin binding to GP Iba, and inhibit thrombin- 
dependent platelet aggregation (Bradford et al., 1997, 
2000; Joseph et al., 1999). Interestingly, the region of 
factor XIIa necessary for binding GP Iba (Bradford et 
al., 2000), has sequence similarity to fibronectin type 11 
modules, as well as epidermal growth factor-like 
domains also found in P-selectin (refer above). 
Platelet adhesion receptors 
Platelet immunoglobulin-like receptors: PECAM-1, 
ICAM-2 and GP VI 
The catalogue of receptors of the immunoglobulin 
(Ig) superfamily on platelets (Fig. 3) has recently 
expanded with the cloning of the collagen receptor, GP 
VI (Clemetson et al., 1999; Ezumi et al., 2000; Jandrot- 
Perrus et al., 2000). GP VI contains two extracellular Ig- 
like domains, a sialomucin core, a transmembrane 
domain and a short cytoplasmic tail. An arginine residue 
within the transmembrane domain, and elements within 
the cytoplasmic tail, mediate the association of GP VI 
with the Fc receptor gamma chain (FcRy) (Zheng et al., 
2001). FcRy is commonly associated with T-cell 
receptors, contains an ITAM (immunoreceptor tyrosine- 
based activation motif) in its cytoplasmic domain, and 
has been shown to be critica1 in GP VI-dependent 
platelet activation (Watson, 1999; Zheng et al., 2001). 
Additional collagen receptors, including a2B1, may also 
mediate platelet responses to collagen (Chiang, 1999; 
Nakamura et al., 1999; Watson, 1999; Kamiguti et al., 
2000). 
Other adhesion receptors of the Ig family found on 
platelets include ICAM-2, which interacts with the 
leukocyte integrin LFA-1 (aLB2), and PECAM-1 that 
interacts with the integrin avB3 (Fig. 1) (Newman et al., 
1990; Diacovo et al., 1994). PECAM-1, found on al1 
vascular cell types, also forms homotypic interactions 
with PECAM-1 on other cells, and regulates endothelial 
cell adhesion at cellular junctions (Andrews and Berndt, 
2000a). PECAM-1, which shows increased expression 
following activation (Metzelaar et al., 1991; Cramer et 
al., 1994), potentially mediates platelet-leukocyte 
adhesion. PECAM-1 also appears to play a role in 
recruitment of protein-tyrosine phosphatases in activated 
platelets, via a cytoplasmic ITIM (immunoreceptor 
tyrosine-based inhibitory motif) domain (Hua et al., 
1998). PECAM-1 may also attenuate platelet responses 
to stimulation by collagen (Patil et al., 2001). ICAM-2 
contributes to neutrophil adhesion to activated platelets 
under flow, along with neutrophil Mac-1 and LFA-1 
(Kuijper et al., 1998). Fibrinogen associated with platelet 
aIIbB3 also plays a role in this process (Weber and 
Springer, 1997; Kuijper et al., 1998). Finally, another 
newly identified Ig family receptor on platelets, FllR, 
contains two extracellular Ig domains, is phosphorylated 
in thrombin- or collagen-stimulated platelets, and has a 
potential though undefined role in platelet function 
(Sobocka et al., 2000). 
GP lb-IX-V-dependent signaling: association with Fc 
receptors andlor GP VI 
Mechanisms of signal transduction following 
engagement of GP Ib-IX-V by vWF remain a source of 
conjecture. For example, is signaling that leads to 
activation of aIIbB3 following platelet adhesion to vWF 
initiated by direct signal transduction through GP Ib-IX- 
V, cross-linking of one or more GP Ib-IX-V complexes, 
or by the involvement of associated receptors? 
PECAM- 1 
Platelets 
Platelets 
Eaidothelial celk 
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Lym~hocytes 
PECAM- 1 
avp3 
Fig. 3. Adhesion receptors of the Ig-like superfamily found on platelets. The stippled bar represents the plasma membrane, with the extracellular 
domain on the right hand side. Solid circles represent potential N-linked glycosylation sites. 
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Supporting a mechanism involving receptor cross- 
linking, platelet activation results from engagement of 
GP Ib-IX-V by native vWF in the presence of ristocetin 
or botrocetin, by asialo-vWF in the absence of 
modulators, by soluble vWF under shear, by 
immobilized vWF under flow, or by recombinant vWF 
A l  domain multimerized by expression on the surface of 
COS-7 cells (Kroll et al., 1996; Schulte am Esch et al., 
1997; Gu et al., 1999; Berndt et al., 2001). In contrast, a 
monomeric fragment of vWF encompassing the A l  
domain, Glu480-Gly718, inhibits binding of native or 
asialo-vWF, but does not induce platelet activation 
(Andrews et al., 1989). A number of presumably 
monovalent, -25-kDa GP Iba-binding viper venom 
proteins of the C-type lectin family similarly block vWF 
binding, but do not activate platelets. However, cross- 
linking of the GP Iba-binding protein, echicetin, by 
IgMk has been reported to activate platelets (Navdaev et 
al., 2001), raising the possibility that cross-linking of GP 
Iba on platelets can initiate signals leading to aIIbB3- 
dependent aggregation. Higher molecular weight forms 
of GP Iba-binding snake proteins, such as 50-kDa 
alboaggregin-A, are also potent platelet agonists 
(Andrews et al., 1996; Kowalska et al., 1998; Falati et 
al., 1999), supporting a receptor cross-linking 
mechanism. Consistent with this supposition, a vWF A l  
domain fragment induced phosphorylation of Syk in 
platelets, and its association with Src, but only native 
multimeric vWF induced activation of aIIbB3 (Satoh et 
al., 2000). Other recent reports suggest alboaggregin-A 
may activate platelets by stimulating GP VI (Asazuma et 
al., 2001; Dormann et al., 2001). In this case, GP Ib-E- 
V may act as a cofactor for alboaggregin-A interacting 
with GP VI, in a comparable rnanner to GP Iba's role in 
promoting thrombin-dependent cleavage of PAR-1. 
Masking GP Iba  by antibodies, venom proteins or 
proteolysis impairs alboaggregin-A-dependent platelet 
aggregation (Andrews et al., 1996; Asazuma et al., 2001; 
Dormam et al., 2001), in a similar manner to the effect 
of GP Iba  blockade on thrombin-dependent PAR-1 
cleavage (De Candia et al., 2001). Both alboaggregin-A 
(Dormann et al., 2001) and thrombin (Ramakrishnan et 
al., 2001) have also been reported to signal through GP 
Iba. It is interesting to speculate that vWF binding to GP 
Iba, like alboaggregin-A and thrombin, might similarly 
lead to stimulation of additional signaling receptors. 
Evidence in the literature supports the linkage of GP 
Ib-IX-V with ITAM-containing Fc receptors (Falati et 
al., 1999; Torti et al., 1999). Firstly, GP I b a  and 
FcgRIIa have been shown by fluorescence energy 
transfer analysis to be proximal on the platelet surface 
(Sullam et al., 1998). Aggregation of platelets by 
FcyRIIa stimuli is blocked by anti-GP Iba antibodies, 
while vWF-dependent signaling is at least partially 
inhibited by the anti-FcyRIIa antibody, IV.3 (Sullam et 
al., 1998; Torti et al., 1999). A direct interaction between 
FcyRIIa and GP Iba has also been shown by yeast two- 
hybrid analysis (Sun et al., 1999). In this case, an 
Arg542-Arg544 sequence of GP Iba was suggested to be 
an interactive site from the affect of mutagenesis of these 
residues on formation of the complex. In addition to GP 
Ib-IX-V, FcyRIIa may also be proximal to aIIbB3 
(Berndt et al., 1993). 
Secondly, FcRy was shown to be co-associated with 
GP I b a  in platelets after their stimulation by 
alboaggregin-A (Falati et al., 1999), a reagent that 
potentially binds GP VI in addition to GPIba (Asazuma 
et al., 2001; Dormann et al., 2001). It is interesting that 
these findings infer an association of GP Iba with FcRy 
andlor a topographical relationship with GP VI. Finally, 
an anti-GP Iba monoclonal antibody, SZ2, that maps to 
the sulfated sequence of GP Iba (Ward et al., 1996; Shen 
et al., 2000), blocks platelet aggregation induced by both 
vWF and collagen (Ruan et al., 1987). This would 
further support the possible topographical association of 
GP Ib-IX-V with either GP VI or other collagen 
receptors such as a2B1. 
lnteraction of GP lb-IX-V with signaling rnolecules, 
14-3-35 and PI 3-kinase 
Signaling molecules associated with GP Ib-IX-V 
have been identified that could be early factors in the 
pathway linking binding of vWF to activation of aIIbR3. 
Firstly, 14-3-35 associated with the cytoplasmic domain 
of GP Ib-IX-V (refer above), may be involved in this 
pathway. In CHO cells co-expressing GP Ib-IX and 
aIIbB3, vWF binding to GP Ib-IX upregulates aIIbB3 
function, and these cells adhere and spread on vWF in an 
aIIbB3-dependent manner (Gu et al., 1999; Yap et al., 
2000; Zaffran et al., 2000). However, deletion of the 14- 
3-35 binding site at the C-terminus of GP Iba inhibited 
GP Ib-IX-induced activation of aIIbB3, and prevented 
cell spreading on vWF (Gu et al., 1999). Shear- 
dependent platelet aggregation initiated by vWF binding 
to GP Iba results in dissociation of 14-3-35 from GP Ib- 
IX (Feng et al., 2000). Spreading of CHO GP Ib- 
IXIaIIbB3 cells on vWF was also blocked by the PI 3- 
kinase inhibitor, wortrnannin (Gu et al., 1999). This 
result complemented other recent findings that PI 3- 
kinase forms a complex with GP Ib-IX-V and 14-3-35 in 
platelets (Munday et al., 2000). In the latter study, the 
association of GP Ib-IX-V with PI-3 kinase and 14-3-32; 
may facilitate translocation of these signaling proteins to 
the activated cytoskeleton. Binding of 14-3-35 to GP IbB 
is also likely to be functionally important in the platelet 
response to vWF, since spreading of CHO cells co- 
transfected with GP Ib-IX and aIIbB3 on vWF is 
blocked by treating the cells with prostaglandin El, that 
increases cAMP levels and induces PKA-dependent 
phosphorylation of GP IbB (Bodnar et al., 1999). 14-3- 
35 binding to GP IbB, therefore, potentially regulates GP 
Ib-IX-V-dependent signaling, as well as cytoskeletal 
rearrangement (Fox and Berndt, 1989). 
GP lb-IX-V and the cytoskeleton 
Cytoskeletal rearrangements in platelets are 
associated with shape change, spreading, secretion 
andlor aggregation (Fox and Meyer, 1998). The GP Ib- 
Platelet adhesion receptors 
IX-V complex is linked to cytoskeletal actin filaments 
via a sequence within the cytoplasmic tail of GP Iba, 
Thr536-Phe568, that binds actin-binding protein 
(Andrews and Fox, 1992; Cunningham et al., 1996). It 
has been shown recently that vWF binding to normal 
platelets, to Glanzmann's thrombasthenic platelets 
lacking aIIbB3, or to CHO cells expressing GP Ib-IX, 
induces actin polymerization and re-organization of the 
cytoskeleton (Yuan et al., 1999). In recombinant GP Iba 
on CHO cells, deletion of the binding site for actin- 
binding protein prevented stable adhesion at high shear, 
whereas adhesion at low shear was normal (Cranmer et 
al., 1999). In contrast, inhibiting actin polymerization 
(using cytochalasin D or latrunculin B) in platelets, 
Glanzmann's thrombasthenic platelets, or GP Ib-IX- 
expressing CHO cells markedly enhanced vWF binding 
(Mistry et al., 2000). Similarly, the shear rate threshold 
for vWF-dependent aggregation was reduced from 3,000 
S-l to 500 S-l. Similarly, Englund et al. showed deleting 
the actin-binding protein binding region from GP Iba 
enhanced vWF binding under static or flow conditions 
(Englund et al., 2001). These results would imply that 
attachment of GP Ib-IX-V to the cytoskeleton in resting 
platelets is a negative regulator of vWF binding. 
Interestingly, in CHO cells expressing recombinant GP 
Iba, deletion of the cytoplasmic sequence involved in 
actin-binding protein attachment abrogated the 
functional gain associated with cytochalasin D treatment 
(Mistry et al., 2000). 
Final comments 
The multi-functional platelet adhesion receptor, GP 
Ib-IX-V, plays a central role in platelet responsiveness to 
injury or pathological shear stress. GP Ib-IX-V binds 
vWF in the vessel wall matrix or plasma, P-selectin on 
platelets or endothelial cells, and Mac-1 on neutrophils 
or monocytes, as  well as  other ligands such as a- 
thrombin, factor XII and high molecular weight 
kininogen. Future studies should define the precise role 
for each of these interactions in the initiation and 
progression of thrombosis. In addition, the binding sites 
on GP Ib-IX-V specific for these different ligands 
remain to be determined. Finally, the way in which 
recognition of these various GP Ib-IX-V-binding ligands 
is  regulated, under normal versus pathological 
conditions, also remains to be resolved. A detailed 
understanding of these elements of GP Ib-IX-V function 
should ultimately enable therapeutic blockade of 
thrombosis, with minimal impairment of hemostasis. 
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